^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor + Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC)
Published date:
07/16/2021
Excerpt:
A total of 30 patients with advanced NSCLC...The median progression-free survial (mPFS) was 5.0 months (95% confidence interval [CI]: 3.179–6.821), and the median overall survival (mOS) was 14.3 months (95% CI: 8.912–19.659)....A combination of PD-1 inhibitors and antiangiogenic targeting agents may be beneficial for patients with advanced or metastatic NSCLC as subsequent treatment, especially for patients with PD-L1 protein expression positive...
DOI:
https://doi.org/10.1111/1759-7714.14078
Source:
Title:
P83.04 - Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent as Subsequent Therapy for Advanced NSCLC
Published date:
01/12/2021
Excerpt:
A total of twenty-nine evaluable patients with advanced or metastatic NSCLC...received the combination therapy of PD-1 inhibitor and anti-angiogenesis were included...Patients with programmed cell death ligand-1 (PD-L1) expression on at least 1% of tumor cells (n=5) has relatively longer mPFS to compared to those with PD-L1-negative tumors (n=13), though no significant difference was observed (11.6 months versus 5.0 months, P=0.967).
